Johnson & Johnson Quick Ratio 2012-2025 | JNJ
Historical quick ratio values for Johnson & Johnson (JNJ) over the last 10 years.
| Johnson & Johnson Quick Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets - Inventory | Current Liabilities | Quick Ratio |
| 2025-12-31 | $41.43B | $54.13B | 0.77 |
| 2025-09-30 | $40.47B | $50.87B | 0.80 |
| 2025-06-30 | $41.09B | $54.18B | 0.76 |
| 2025-03-31 | $58.89B | $56.90B | 1.04 |
| 2024-12-31 | $43.45B | $50.32B | 0.86 |
| 2024-09-30 | $40.65B | $51.76B | 0.79 |
| 2024-06-30 | $45.65B | $53.93B | 0.85 |
| 2024-03-31 | $45.62B | $48.73B | 0.94 |
| 2023-12-31 | $42.31B | $46.28B | 0.91 |
| 2023-09-30 | $42.51B | $44.37B | 0.96 |
| 2023-06-30 | $47.68B | $54.17B | 0.88 |
| 2023-03-31 | $51.58B | $60.37B | 0.85 |
| 2022-12-31 | $45.03B | $55.80B | 0.81 |
| 2022-09-30 | $53.56B | $45.54B | 1.18 |
| 2022-06-30 | $52.41B | $44.82B | 1.17 |
| 2022-03-31 | $49.43B | $43.39B | 1.14 |
| 2021-12-31 | $50.59B | $45.23B | 1.12 |
| 2021-09-30 | $49.50B | $44.56B | 1.11 |
| 2021-06-30 | $43.67B | $38.72B | 1.13 |
| 2021-03-31 | $42.58B | $40.93B | 1.04 |
| 2020-12-31 | $41.89B | $42.49B | 0.99 |
| 2020-09-30 | $47.98B | $38.85B | 1.24 |
| 2020-06-30 | $36.47B | $36.77B | 0.99 |
| 2020-03-31 | $35.36B | $33.69B | 1.05 |
| 2019-12-31 | $36.25B | $35.96B | 1.01 |
| 2019-09-30 | $35.16B | $35.16B | 1.00 |
| 2019-06-30 | $32.54B | $31.35B | 1.04 |
| 2019-03-31 | $32.90B | $29.11B | 1.13 |
| 2018-12-31 | $37.43B | $31.23B | 1.20 |
| 2018-09-30 | $38.52B | $27.44B | 1.40 |
| 2018-06-30 | $36.63B | $27.49B | 1.33 |
| 2018-03-31 | $33.75B | $27.08B | 1.25 |
| 2017-12-31 | $34.32B | $30.54B | 1.12 |
| 2017-09-30 | $32.31B | $31.81B | 1.02 |
| 2017-06-30 | $29.09B | $28.87B | 1.01 |
| 2017-03-31 | $54.47B | $25.12B | 2.17 |
| 2016-12-31 | $56.89B | $26.29B | 2.16 |
| 2016-09-30 | $54.83B | $23.23B | 2.36 |
| 2016-06-30 | $57.77B | $21.54B | 2.68 |
| 2016-03-31 | $54.57B | $22.13B | 2.47 |
| 2015-12-31 | $52.16B | $27.75B | 1.88 |
| 2015-09-30 | $55.29B | $25.26B | 2.19 |
| 2015-06-30 | $52.70B | $24.51B | 2.15 |
| 2015-03-31 | $50.11B | $23.84B | 2.10 |
| 2014-12-31 | $47.56B | $25.03B | 1.90 |
| 2014-09-30 | $51.55B | $22.98B | 2.24 |
| 2014-06-30 | $51.96B | $24.36B | 2.13 |
| 2014-03-31 | $49.36B | $23.84B | 2.07 |
| 2013-12-31 | $48.53B | $25.68B | 1.89 |
| 2013-09-30 | $44.05B | $25.84B | 1.71 |
| 2013-06-30 | $43.45B | $23.77B | 1.83 |
| 2013-03-31 | $39.54B | $22.52B | 1.76 |
| 2012-12-31 | $38.62B | $24.26B | 1.59 |
| 2012-09-30 | $36.98B | $23.94B | 1.55 |
| 2012-06-30 | $33.92B | $23.85B | 1.42 |
| 2012-03-31 | $50.21B | $21.20B | 2.37 |
| 2011-12-31 | $48.03B | $22.81B | 2.11 |
| 2011-09-30 | $47.02B | $21.69B | 2.17 |
| 2011-06-30 | $46.26B | $20.99B | 2.20 |
| 2011-03-31 | $43.02B | $24.01B | 1.79 |
| 2010-12-31 | $41.93B | $23.07B | 1.82 |
| 2010-09-30 | $37.31B | $17.41B | 2.14 |
| 2010-06-30 | $33.95B | $17.16B | 1.98 |
| 2010-03-31 | $33.55B | $18.50B | 1.81 |
| 2009-12-31 | $34.36B | $21.73B | 1.58 |
| 2009-09-30 | $30.03B | $19.25B | 1.56 |
| 2009-06-30 | $30.02B | $19.89B | 1.51 |
| 2009-03-31 | $29.48B | $21.33B | 1.38 |
| 2008-12-31 | $29.33B | $20.85B | 1.41 |
| 2008-09-30 | $31.12B | $22.73B | 1.37 |
| 2008-06-30 | $30.12B | $21.78B | 1.38 |
| 2008-03-31 | $28.24B | $22.07B | 1.28 |
| 2007-12-31 | $24.84B | $19.84B | 1.25 |
| 2007-09-30 | $23.53B | $19.33B | 1.22 |
| 2007-06-30 | $20.65B | $18.98B | 1.09 |
| 2007-03-31 | $19.63B | $19.66B | 1.00 |
| 2006-12-31 | $18.09B | $19.16B | 0.94 |
| 2006-09-30 | $26.84B | $12.06B | 2.23 |
| 2006-06-30 | $27.20B | $12.19B | 2.23 |
| 2006-03-31 | $29.51B | $13.19B | 2.24 |
| 2005-12-31 | $27.52B | $12.64B | 2.18 |
| 2005-09-30 | $26.56B | $12.05B | 2.21 |
| 2005-06-30 | $24.76B | $11.64B | 2.13 |
| 2005-03-31 | $24.95B | $12.98B | 1.92 |
| 2004-12-31 | $23.58B | $13.93B | 1.69 |
| 2004-09-30 | $23.15B | $12.33B | 1.88 |
| 2004-06-30 | $21.13B | $12.06B | 1.75 |
| 2004-03-31 | $20.84B | $12.45B | 1.67 |
| 2003-12-31 | $19.41B | $13.45B | 1.44 |
| 2003-09-30 | $18.41B | $12.78B | 1.44 |
| 2003-06-30 | $17.70B | $12.84B | 1.38 |
| 2003-03-31 | $16.93B | $11.46B | 1.48 |
| 2002-12-31 | $15.96B | $11.45B | 1.39 |
| 2002-09-30 | $15.75B | $10.70B | 1.47 |
| 2002-06-30 | $15.50B | $10.57B | 1.47 |
| 2002-03-31 | $15.31B | $8.30B | 1.85 |
| 2001-12-31 | $15.48B | $8.04B | 1.93 |
| 2001-09-30 | $16.07B | $7.50B | 2.14 |
| 2001-06-30 | $15.28B | $7.35B | 2.08 |
| 2001-03-31 | $13.61B | $6.82B | 2.00 |
| 2000-12-31 | $13.79B | $7.26B | 1.90 |
| 2000-09-30 | $12.20B | $6.67B | 1.83 |
| 2000-06-30 | $11.31B | $6.61B | 1.71 |
| 2000-03-31 | $10.92B | $7.13B | 1.53 |
| 1999-12-31 | $10.11B | $7.45B | 1.36 |
| 1999-09-30 | $9.77B | $6.98B | 1.40 |
| 1999-06-30 | $9.18B | $7.89B | 1.16 |
| 1999-03-31 | $8.66B | $7.87B | 1.10 |
| 1998-12-31 | $8.28B | $8.16B | 1.01 |
| 1998-09-30 | $9.28B | $5.40B | 1.72 |
| 1998-06-30 | $8.64B | $5.14B | 1.68 |
| 1998-03-31 | $8.42B | $5.22B | 1.62 |
| 1997-12-31 | $8.05B | $5.28B | 1.52 |
| 1997-09-30 | $8.51B | $5.48B | 1.55 |
| 1997-06-30 | $7.64B | $5.31B | 1.44 |
| 1997-03-31 | $7.43B | $5.45B | 1.36 |
| 1996-12-31 | $6.87B | $5.18B | 1.33 |
| 1996-09-30 | $6.97B | $4.93B | 1.41 |
| 1996-06-30 | $6.74B | $4.40B | 1.53 |
| 1996-03-31 | $6.57B | $4.42B | 1.49 |
| 1995-12-31 | $5.66B | $4.39B | 1.29 |
| 1995-09-30 | $5.71B | $4.31B | 1.33 |
| 1995-06-30 | $5.47B | $4.29B | 1.28 |
| 1995-03-31 | $5.24B | $4.17B | 1.26 |
| 1994-12-31 | $4.52B | $4.27B | 1.06 |
| 1994-09-30 | $4.62B | $4.41B | 1.05 |
| 1994-06-30 | $4.22B | $3.20B | 1.32 |
| 1994-03-31 | $3.83B | $3.15B | 1.22 |
| 1993-12-31 | $3.50B | $3.21B | 1.09 |
| 1993-09-30 | $3.79B | $3.34B | 1.14 |
| 1993-06-30 | $3.73B | $3.04B | 1.23 |
| 1993-03-31 | $3.63B | $3.15B | 1.16 |
| 1992-12-31 | $3.68B | $3.43B | 1.07 |
| 1992-09-30 | $3.98B | $3.29B | 1.21 |
| 1992-06-30 | $3.56B | $3.35B | 1.06 |
| 1992-03-31 | $3.17B | $2.76B | 1.15 |
| 1991-12-31 | $3.23B | $2.69B | 1.20 |
| 1991-09-30 | $3.20B | $2.39B | 1.34 |
| 1991-06-30 | $3.01B | $2.53B | 1.19 |
| 1991-03-31 | $3.06B | $2.30B | 1.33 |
| 1990-12-31 | $3.12B | $2.62B | 1.19 |
| 1990-09-30 | $3.36B | $2.92B | 1.15 |
| 1990-06-30 | $3.16B | $2.82B | 1.12 |
| 1990-03-31 | $2.78B | $2.57B | 1.08 |
| 1989-12-31 | $2.42B | $1.93B | 1.26 |
| 1989-09-30 | $2.41B | $1.84B | 1.31 |
| 1989-06-30 | $2.51B | $2.12B | 1.18 |
| 1989-03-31 | $2.41B | $1.94B | 1.24 |
| 1988-12-31 | $2.23B | $1.87B | 1.19 |
| 1988-09-30 | $2.27B | $2.16B | 1.05 |
| 1988-06-30 | $2.50B | $2.24B | 1.12 |
| 1988-03-31 | $2.43B | $2.00B | 1.22 |
| 1987-12-31 | $2.11B | $1.76B | 1.20 |
| 1987-09-30 | $2.57B | $2.14B | 1.20 |
| 1987-06-30 | $2.38B | $2.54B | 0.94 |
| 1987-03-31 | $2.16B | $2.42B | 0.89 |
| 1986-12-31 | $2.19B | $2.29B | 0.96 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $586.690B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |